{"id":"cggv:830b11ca-6ec1-4aa9-bb44-379f03f738c7v1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:830b11ca-6ec1-4aa9-bb44-379f03f738c7_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10005","date":"2021-10-21T00:46:55.602Z","role":"Publisher"},{"id":"cggv:830b11ca-6ec1-4aa9-bb44-379f03f738c7_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10005","date":"2021-10-21T00:46:41.341Z","role":"Approver"}],"evidence":[{"id":"cggv:830b11ca-6ec1-4aa9-bb44-379f03f738c7_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:830b11ca-6ec1-4aa9-bb44-379f03f738c7_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":12},{"id":"cggv:67cbf850-039d-491b-bb42-247e07178c80_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:67cbf850-039d-491b-bb42-247e07178c80","type":"Proband","allele":[{"id":"cggv:e7bef812-ad72-47e0-b9b0-e74fa6e9987f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032634.4(PIGO):c.2869C>T (p.Leu957Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA129968"}},{"id":"cggv:0c3c3f3d-9a21-4838-8812-fd4cc9f0a45c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032634.3(PIGO):c.2361dupC","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA129969"}}],"firstTestingMethod":"Exome sequencing","sex":"Female","variant":[{"id":"cggv:c061174b-f354-4c45-8ced-7f7351f6c5f9_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:e7bef812-ad72-47e0-b9b0-e74fa6e9987f"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/22683086","type":"dc:BibliographicResource","dc:abstract":"Hyperphosphatasia with mental retardation syndrome (HPMRS), an autosomal-recessive form of intellectual disability characterized by facial dysmorphism, seizures, brachytelephalangy, and persistent elevated serum alkaline phosphatase (hyperphosphatasia), was recently shown to be caused by mutations in PIGV, a member of the glycosylphosphatidylinositol (GPI)-anchor-synthesis pathway. However, not all individuals with HPMRS harbor mutations in this gene. By exome sequencing, we detected compound-heterozygous mutations in PIGO, a gene coding for a membrane protein of the same molecular pathway, in two siblings with HPMRS, and we then found by Sanger sequencing further mutations in another affected individual; these mutations cosegregated in the investigated families. The mutant transcripts are aberrantly spliced, decrease the membrane stability of the protein, or impair enzyme function such that GPI-anchor synthesis is affected and the level of GPI-anchored substrates localized at the cell surface is reduced. Our data identify PIGO as the second gene associated with HPMRS and suggest that a deficiency in GPI-anchor synthesis is the underlying molecular pathomechanism of HPMRS.","dc:creator":"Krawitz PM","dc:date":"2012","dc:title":"Mutations in PIGO, a member of the GPI-anchor-synthesis pathway, cause hyperphosphatasia with mental retardation."}},{"id":"cggv:2dcba93d-05b3-4577-909f-daea5155388a_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:0c3c3f3d-9a21-4838-8812-fd4cc9f0a45c"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/22683086"}],"rdfs:label":"22683086_FamilyA_II:1"},{"id":"cggv:2dcba93d-05b3-4577-909f-daea5155388a","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:2dcba93d-05b3-4577-909f-daea5155388a_variant_evidence_item"},{"id":"cggv:2dcba93d-05b3-4577-909f-daea5155388a_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Expression in CHO cells showed impaired GPI linking"}],"strengthScore":2},{"id":"cggv:c061174b-f354-4c45-8ced-7f7351f6c5f9","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:c061174b-f354-4c45-8ced-7f7351f6c5f9_variant_evidence_item"},{"id":"cggv:c061174b-f354-4c45-8ced-7f7351f6c5f9_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Expression in CHO cells showed impaired GPI linking"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:41262e6b-69ed-47c7-8e0b-38d933d1dfd4_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:41262e6b-69ed-47c7-8e0b-38d933d1dfd4","type":"Proband","allele":[{"id":"cggv:7a62fe85-7a52-4caa-992f-3568845b1250","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032634.4(PIGO):c.2497_2498del (p.Ala834CysfsTer131)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA863537001"}},{"id":"cggv:ef6a0524-6bd8-433c-9f77-f9783233da54","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032634.4(PIGO):c.1109A>G (p.Asn370Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1067428"}}],"phenotypes":["obo:HP_0003155","obo:HP_0000365","obo:HP_0001999","obo:HP_0012758"],"sex":"Female","variant":[{"id":"cggv:c6d175fa-eb8a-4d9c-a2ed-2f255824b6e7_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:7a62fe85-7a52-4caa-992f-3568845b1250"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/28337824","type":"dc:BibliographicResource","dc:abstract":"Inherited GPI (glycosylphosphatidylinositol) deficiencies (IGDs), a recently defined group of diseases, show a broad spectrum of symptoms. Hyperphosphatasia mental retardation syndrome, also known as Mabry syndrome, is a type of IGDs. There are at least 26 genes involved in the biosynthesis and transport of GPI-anchored proteins; however, IGDs constitute a rare group of diseases, and correlations between the spectrum of symptoms and affected genes or the type of mutations have not been shown. Here, we report four newly identified and five previously described Japanese families with PIGO (phosphatidylinositol glycan anchor biosynthesis class O) deficiency. We show how the clinical severity of IGDs correlates with flow cytometric analysis of blood, functional analysis using a PIGO-deficient cell line, and the degree of hyperphosphatasia. The flow cytometric analysis and hyperphosphatasia are useful for IGD diagnosis, but the expression level of GPI-anchored proteins and the degree of hyperphosphatasia do not correlate, although functional studies do, with clinical severity. Compared with PIGA (phosphatidylinositol glycan anchor biosynthesis class A) deficiency, PIGO deficiency shows characteristic features, such as Hirschsprung disease, brachytelephalangy, and hyperphosphatasia. This report shows the precise spectrum of symptoms according to the severity of mutations and compares symptoms between different types of IGD.","dc:creator":"Tanigawa J","dc:date":"2017","dc:title":"Phenotype-genotype correlations of PIGO deficiency with variable phenotypes from infantile lethality to mild learning difficulties."}},{"id":"cggv:1a3960e8-9ce3-42aa-9500-8903032635c6_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:ef6a0524-6bd8-433c-9f77-f9783233da54"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28337824"}],"rdfs:label":"28337824_FamilyA_AII-2"},{"id":"cggv:1a3960e8-9ce3-42aa-9500-8903032635c6","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:1a3960e8-9ce3-42aa-9500-8903032635c6_variant_evidence_item"},{"id":"cggv:1a3960e8-9ce3-42aa-9500-8903032635c6_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Expression of N370S in PIGO-knockout HEK293 cells showed severely impaired GPI-AP expression compared to WT"}],"strengthScore":0.5},{"id":"cggv:c6d175fa-eb8a-4d9c-a2ed-2f255824b6e7","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:c6d175fa-eb8a-4d9c-a2ed-2f255824b6e7_variant_evidence_item"},{"id":"cggv:c6d175fa-eb8a-4d9c-a2ed-2f255824b6e7_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Expression in PIGO-knockout HEK293 cells blocked GPI-AP expression compared to WT"}],"strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:b4fa08d7-3377-48a9-b4ec-cdbe4168828f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:b4fa08d7-3377-48a9-b4ec-cdbe4168828f","type":"Proband","allele":[{"id":"cggv:e7bef812-ad72-47e0-b9b0-e74fa6e9987f"},{"id":"cggv:4fc59a67-6f40-4e80-bc84-36a8ba392aec","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032634.3(PIGO):c.3069+5G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA129970"}}],"phenotypes":["obo:HP_0012758","obo:HP_0003155","obo:HP_0001999","obo:HP_0001250"],"sex":"Female","variant":[{"id":"cggv:267f166d-b3f8-4637-ac9f-05d8be51785e_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:e7bef812-ad72-47e0-b9b0-e74fa6e9987f"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/22683086"},{"id":"cggv:5d2f3383-3e36-4ba1-917d-c0d6e34af931_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:4fc59a67-6f40-4e80-bc84-36a8ba392aec"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/22683086"}],"rdfs:label":"22683086_FamilyB_Proband"},{"id":"cggv:267f166d-b3f8-4637-ac9f-05d8be51785e","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:267f166d-b3f8-4637-ac9f-05d8be51785e_variant_evidence_item"},{"id":"cggv:267f166d-b3f8-4637-ac9f-05d8be51785e_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Expression in CHO cells showed impaired GPI linking"}],"strengthScore":0.5},{"id":"cggv:5d2f3383-3e36-4ba1-917d-c0d6e34af931","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:5d2f3383-3e36-4ba1-917d-c0d6e34af931_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:edc414b9-be13-497f-8747-184011e4b5ab_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:edc414b9-be13-497f-8747-184011e4b5ab","type":"Proband","allele":[{"id":"cggv:1377fcb7-e2c8-49fe-9d1d-3931a2eaec45","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032634.4(PIGO):c.2646del (p.Gly883ValfsTer56)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2499214033"}},{"id":"cggv:ca1c40f3-804c-4289-9cd6-9906fe6e2332","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032634.4(PIGO):c.1031T>A (p.Met344Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5040744"}}],"firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0012758","obo:HP_0003155","obo:HP_0001250"],"sex":"Female","variant":[{"id":"cggv:eb84cac0-b029-45b2-99d5-ce54f741adf7_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:1377fcb7-e2c8-49fe-9d1d-3931a2eaec45"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28337824"},{"id":"cggv:f443970c-3bec-40a2-9dd5-7c398bd0b97c_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:ca1c40f3-804c-4289-9cd6-9906fe6e2332"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28337824"}],"rdfs:label":"28337824_FamilyC_II-2"},{"id":"cggv:eb84cac0-b029-45b2-99d5-ce54f741adf7","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:eb84cac0-b029-45b2-99d5-ce54f741adf7_variant_evidence_item"},{"id":"cggv:eb84cac0-b029-45b2-99d5-ce54f741adf7_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"PIGO-knockout HEK293 cells showed absent GPI-AP expression when transfected with c.2646del compared to WT"}],"strengthScore":2},{"id":"cggv:f443970c-3bec-40a2-9dd5-7c398bd0b97c","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:f443970c-3bec-40a2-9dd5-7c398bd0b97c_variant_evidence_item"},{"id":"cggv:f443970c-3bec-40a2-9dd5-7c398bd0b97c_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"PIGO-knockout HEK293 cells transiently transfected with M344K or WT; protein expression was lower in cells expressing M344K than WT"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:d74929d5-8cb8-46f2-8646-d9b7b22fd191_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:d74929d5-8cb8-46f2-8646-d9b7b22fd191","type":"Proband","allele":[{"id":"cggv:1377fcb7-e2c8-49fe-9d1d-3931a2eaec45"},{"id":"cggv:ef6a0524-6bd8-433c-9f77-f9783233da54"}],"firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0001999","obo:HP_0000365","obo:HP_0003155","obo:HP_0001250","obo:HP_0012758"],"sex":"Female","variant":[{"id":"cggv:53dc455e-b72d-4b5f-8e90-3e937222eb63_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:ef6a0524-6bd8-433c-9f77-f9783233da54"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28337824"},{"id":"cggv:4fc10137-d3c2-42b2-98b6-924a9bdeb38e_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:1377fcb7-e2c8-49fe-9d1d-3931a2eaec45"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28337824"}],"rdfs:label":"28337824_BII-2"},{"id":"cggv:53dc455e-b72d-4b5f-8e90-3e937222eb63","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:53dc455e-b72d-4b5f-8e90-3e937222eb63_variant_evidence_item"},{"id":"cggv:53dc455e-b72d-4b5f-8e90-3e937222eb63_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Expression of N370S in PIGO-knockout HEK293 cells showed severely impaired GPI-AP expression compared to WT"}],"strengthScore":0.5},{"id":"cggv:4fc10137-d3c2-42b2-98b6-924a9bdeb38e","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:4fc10137-d3c2-42b2-98b6-924a9bdeb38e_variant_evidence_item"},{"id":"cggv:4fc10137-d3c2-42b2-98b6-924a9bdeb38e_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Expression in PIGO-knockout HEK293 cells showed absent GPI-AP expression compared to WT"}],"strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:a34bd2ae-7560-4194-9947-d3b717cc3dab_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:a34bd2ae-7560-4194-9947-d3b717cc3dab","type":"Proband","allele":[{"id":"cggv:c8a76f72-06cb-4688-8664-a18ddcf27aec","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032634.4(PIGO):c.1355_1356del (p.Ala452fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658797196"}},{"id":"cggv:1b27d7f1-f636-4cba-9b19-8007645a4200","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032634.4(PIGO):c.458T>C (p.Phe153Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5040942"}}],"firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0003155","obo:HP_0001250","obo:HP_0012758"],"sex":"Male","variant":[{"id":"cggv:a0d9883c-5713-42fa-b0da-4e093f37cbe9_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:1b27d7f1-f636-4cba-9b19-8007645a4200"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/27177984","type":"dc:BibliographicResource","dc:abstract":"Hyperphosphatasia mental retardation syndrome (Mabry syndrome) is an autosomal recessive disorder. We aim to analyze two Chinese patients diagnosed as Mabry syndrome.","dc:creator":"Xue J","dc:date":"2016","dc:title":"Clinical and genetic analysis of two Chinese infants with Mabry syndrome."}},{"id":"cggv:a3b2f8d2-b8e8-4992-9684-dd52b359948c_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c8a76f72-06cb-4688-8664-a18ddcf27aec"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/27177984"}],"rdfs:label":"27177984_Proband2"},{"id":"cggv:a0d9883c-5713-42fa-b0da-4e093f37cbe9","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:a0d9883c-5713-42fa-b0da-4e093f37cbe9_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:a3b2f8d2-b8e8-4992-9684-dd52b359948c","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:a3b2f8d2-b8e8-4992-9684-dd52b359948c_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:f07fa3fd-3fd1-4e15-86e8-405cf8cc8716_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:f07fa3fd-3fd1-4e15-86e8-405cf8cc8716","type":"Proband","allele":[{"id":"cggv:968725c7-bdd5-4df2-83e1-cc4147e7110b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032634.4(PIGO):c.1288C>T (p.Gln430Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA192711911"}},{"id":"cggv:45a307a3-33ea-4c45-9670-82c7963480e6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032634.4(PIGO):c.389C>A (p.Thr130Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA373324393"}}],"detectionMethod":"Quad exome sequencing (both affected siblings and both unaffected parents sequenced)","firstTestingMethod":"Exome sequencing","sex":"Male","variant":[{"id":"cggv:144edb72-2e3d-4ace-aab9-4bb4f8b70363_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:968725c7-bdd5-4df2-83e1-cc4147e7110b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24417746","type":"dc:BibliographicResource","dc:abstract":"Aberrations in the glycosylphosphatidylinositol (GPI)-anchor biosynthesis pathway constitute a subclass of congenital disorders of glycosylation, and mutations in seven genes involved in this pathway have been identified. Among them, mutations in PIGV and PIGO, which are involved in the late stages of GPI-anchor synthesis, and PGAP2, which is involved in fatty-acid GPI-anchor remodeling, are all causative for hyperphosphatasia with mental retardation syndrome (HPMRS). Using whole exome sequencing, we identified novel compound heterozygous PIGO mutations (c.389C>A [p.Thr130Asn] and c.1288C>T [p.Gln430*]) in two siblings, one of them having epileptic encephalopathy. GPI-anchored proteins (CD16 and CD24) on blood granulocytes were slightly decreased compared with a control and his mother. Our patients lacked the characteristic features of HPMRS, such as facial dysmorphology (showing only a tented mouth) and hypoplasia of distal phalanges, and had only a mild elevation of serum alkaline phosphatase (ALP). Our findings therefore expand the clinical spectrum of GPI-anchor deficiencies involving PIGO mutations to include epileptic encephalopathy with mild elevation of ALP. ","dc:creator":"Nakamura K","dc:date":"2014","dc:title":"PIGO mutations in intractable epilepsy and severe developmental delay with mild elevation of alkaline phosphatase levels."}},{"id":"cggv:96ec7b6d-16cf-4861-96aa-5eec3424f76b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:45a307a3-33ea-4c45-9670-82c7963480e6"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24417746"}],"rdfs:label":"24417746_Family1_II:1"},{"id":"cggv:144edb72-2e3d-4ace-aab9-4bb4f8b70363","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:144edb72-2e3d-4ace-aab9-4bb4f8b70363_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:96ec7b6d-16cf-4861-96aa-5eec3424f76b","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:96ec7b6d-16cf-4861-96aa-5eec3424f76b_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"cggv:830b11ca-6ec1-4aa9-bb44-379f03f738c7_experimental_evidence_line","type":"EvidenceLine","specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0}],"evidenceStrength":"Definitive","sequence":3519,"specifiedBy":"GeneValidityCriteria8","strengthScore":12,"subject":{"id":"cggv:dd001b13-78bf-4873-ba6f-7d4cc532d06d","type":"GeneValidityProposition","disease":"obo:MONDO_0100038","gene":"hgnc:23215","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"PIGO was first reported in relation to autosomal recessive complex neurodevelopmental disorder in 2012 (Krawitz et al., PMID: 22683086). At least 15 variants have been reported in\nhumans. Evidence supporting this gene-disease relationship includes case-level data (12 points). Variants in this gene have been reported in at least 7 probands in 4 publications (PMID: 24417746, 27177984, 22683086, 28337824). More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism for disease is recessive loss of function (Krawitz et al., PMID: 22683086). Of note, hyperphosphatasia is not a defining feature of this condition, but rather a biochemical phenotype that is occasionally detected in affected individuals. In summary, PIGO is definitively associated with an autosomal recessive complex neurodevelopmental disorder . This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Epilepsy Working Group on 07/20/21 (SOP Version 8).","dc:isVersionOf":{"id":"cggv:830b11ca-6ec1-4aa9-bb44-379f03f738c7"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}